Bayer to Expand Into Molecular Imaging With Acquisition of Innovative Pan-Amyloid Radiotracers From Attralus

Bayer, a leading company in key areas of radiology and cardiology, and Attralus, Inc. (Attralus), a clinical stage biopharmaceutical company focused on developing medicines and diagnostics for systemic amyloidosis, today announced that the companies have entered into definitive agreements for Bayer to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m), two investigational molecular imaging agents for the diagnosis of cardiac amyloidosis, from Attralus. This strategic acquisition reinforces Bayer’s ambition to expand in the rapidly growing field of molecular imaging and supports the company’s broader precision cardiology strategy.

“With this strategic acquisition and the integration of novel molecular tracers into our development portfolio, we are advancing Bayer’s innovation strategy,” said Stefan Oelrich, Member of the Board of Management of Bayer AG and President of Bayer’s Pharmaceuticals Division. “AT-01 and AT-05 are precisely engineered to detect cardiac amyloidosis with high accuracy, enabling timely intervention and improved patient outcomes – a clear extension of our commitment to tackling cardiovascular disease and addressing significant unmet needs.”

The acquired molecular imaging portfolio consists of AT-01 (124-Iodine-evuzamitide, a tracer for Positron Emission Tomography; PET) in Phase III of clinical development and AT-05 (PAR-Peptide + technetium-99m, a tracer for Single Photon Emission Computed Tomography; SPECT) in Phase I of clinical development, focused on the diagnosis of cardiac amyloidosis. The development of these tracers has the potential to address the urgent need for earlier and accurate diagnosis of systemic and specifically cardiac amyloidosis, a rarely diagnosed and often fatal heart disease that affects an estimated 400,000 people globally. With current methods, these conditions are often underdiagnosed and difficult to detect.

“With new therapies emerging for often insufficiently treated conditions such as cardiac amyloidosis, it becomes increasingly relevant to precisely detect and monitor diseases on the molecular level,” said Nelson Ambrogio, President Radiology at Bayer. “This acquisition marks our entry into diagnostic tracers. Leveraging our expertise in medical imaging – including our pipeline and portfolio in advanced fluid delivery devices for nuclear medicine – it supports our ambition to expand in the growing field of molecular imaging. Building on Attralus’ research and development expertise, we will further advance scientific progress with the aim to broaden diagnostic options and make a meaningful difference for people living with cardiac amyloidosis.”